Merck returns to lucrative eye disease market in up to $3B deal for EyeBio

Kyle LaHucik

Senior Reporter

A decade after departing the ophthalmology drug market, Merck is launching a return to the field in a $1.3 billion upfront cash acquisition for Series …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck returns to lucrative eye disease market in up to $3B deal for EyeBio

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Mer­ck re­turns to lu­cra­tive eye dis­ease mar­ket in up to $3B deal for Eye­Bio

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Merck returns to lucrative eye disease market in up to $3B deal for EyeBio